AstraZeneca invests $30M to expand global innovation centre in Chennai
This investment will convert Chennai-based GITC, the biggest one by the company as it looks to tap on artificial intelligence and technological prowess to deliver healthcare solutions.
AstraZeneca India Private Limited on Thursday announced an investment of $30 million (Rs 250 crore) to expand its Global Innovation and Technology Centre (GITC) in Tamil Nadu.
AstraZeneca inaugurated its Global Capability Centre (GCC) centre in Chennai, which is expected to be its largest one globally. This expansion aims to streamline operations, emphasising efficiency, innovation, and developing 1,300 positions by next year which are aligned with these objectives.
The expanded GCC is expected to drive the company to “leverage technologies such as enterprise platforms, artificial intelligence, machine learning, data science, and supply chain analytics to shape healthcare outcomes.”
The event was attended by Dr TRB Rajaa, Minister of Industries for Tamil Nadu, Christina Scott CMG, British Deputy High Commissioner, and AstraZeneca’s Vice President for Asia Area, Sylvia Varela. AstraZeneca's "investment will not only enhance our state's capabilities in the pharmaceutical and healthcare sectors but also spur technological advancements and economic development.” said Rajaa in a statement.
“This new campus will be home to 4000 high-quality jobs in Chennai,” TRB Rajaa said on X.
The GITC facility in Chennai currently occupies 334,000 square feet of office space at Ramanujan IT City. With AstraZeneca’s entry into the landscape it further plans to add about 180,000 square feet over the next six months
The AZIPL is the Global Capability Centre of the British-Swedish pharmaceutical company which entered the Indian markets nearly 45 years ago. The company developed the much sought-after Covid-19 vaccine, Covishield. It currently employs more than 4000 people in the country
Edited by Affirunisa Kankudti
